Nucleic acid duplexes
AssigneeAlpha Anomeric SAS
InventorsWolfgang RENNER, Damien EVÉQUOZ
Life of this patent
Estimating the term…
Loading patent…
AssigneeAlpha Anomeric SAS
InventorsWolfgang RENNER, Damien EVÉQUOZ
Estimating the term…
The present invention relates to a compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first oligonucleotide and said second oligomeric compound comprises a second oligonucleotide, wherein said first oligonucleotide has a nucleobase sequence that is complementary to a nucleic acid target, and wherein preferably said first oligonucleotide is an antisense oligonucleotide; and wherein said second oligonucleotide has a nucleobase sequence that is complementary to the nucleobase sequence of the first oligonucleotide; and wherein the affinity of said first oligonucleotide to said second oligonucleotide is lower than the affinity of said first oligonucleotide to the fully complementary unmodified RNA oligonucleotide of said first oligonucleotide; or wherein the biostability of said second oligonucleotide is lower than the biostability of said first oligonucleotide.
A compound comprising a first oligomeric compound and a second oligomeric compound, wherein the first oligomeric compound comprises a first oligonucleotide and said second oligomeric compound comprises a second oligonucleotide, wherein
The compound of any one of the preceding claims, wherein at most five, preferably at most four, further preferably at most three, more preferably at most two, and yet more preferably only one of all internucleoside linkages of said first oligonucleotide are phosphorothioate internucleoside linkages, and the remaining internucleoside linkages of said first oligonucleotide are phosphodiester linkages.
The compound of any one of the preceding claims, wherein all internucleoside linkages of said first oligonucleotide are phosphodiester linkages.
The compound of any one of the preceding claims, wherein at least 70% of the sugar moieties of said second oligonucleotide are unmodified DNA sugar moieties, preferably wherein at least 80%, more preferably at least 90%, more preferably at least 95%, and yet more preferably 100% of the sugar moieties of said second oligonucleotide are unmodified DNA sugar moieties, and wherein preferably at most three of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′-end and/or at the 3′-end of said second oligonucleotide.
The compound of any one of the preceding claims, wherein each sugar moiety of said second oligonucleotide is an unmodified DNA sugar moiety, wherein at most four of all internucleoside linkages of said second oligonucleotide are phosphorothioate internucleoside linkages, wherein preferably said phosphorothioate internucleoside linkages are positioned at the 5′-end and/or at the 3′-end of said second oligonucleotide.
A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.